TOKYO & MALVERN, PA. & GENT, BELGIUM--(Business Wire / Korea Newswire)--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay systems. The Research Use Only (RUO) assay is now available in the United States, and it will be available in Japan, Europe and other regions* as of September this year. The Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the quantitative measurement of glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes.

“In 2023 we already introduced two new important neuro assays for RUO-based detection of Neurofilament Light (NfL) and pTau 217,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “We continue our engagement in biomarker-based testing for neurological diseases with the Lumipulse G GFAP, affirming our commitment to play an essential partnering role in both research and clinical routine.”

The Lumipulse G GFAP assay will allow the scientific community and clinical research professionals to further study and understand the potential clinical utility of this promising astrocytic biomarker for neurological conditions such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and brain-related acute traumatic injuries or stroke.[1]

With the fully automated random-access LUMIPULSE G platform, professionals will be able to measure GFAP in a user-friendly and reliable way. This standardized immunoassay platform is already widely available in labs for routine and research testing of neurological disease-related biomarkers. The new assay meets the necessary quality, throughput, and regulatory requirements to support potential routine testing of GFAP in combination with other tests from the Fujirebio neuro biomarker menu.

About Fujirebio

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in high-quality in vitro diagnostics (IVD) testing with more than 50 years’ accumulated experience in the research, development, production and worldwide commercialization of robust IVD products.

Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/neuro.

References:

[1] Abdelhak, A., Foschi, M., Abu-Rumeileh, S. et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol 18, 158-172 (2022). https://doi.org/10.1038/s41582-021-00616-3
* Please contact your local Fujirebio representative for the availability of this product in your country

Lumipulse is a registered trademark of Fujirebio Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240726266467/en/

Website: https://www.fujirebio.com/en Contact FUJIREBIO
For media
Public Relations Section, Public Relations/Sustainability Department,
H.U. Group Holdings, Inc.
+81-3-6279-0884
pr@hugp.com

For investors and analysts
IR/SR Dept.
+81-3-5909-3337
ir@hugp.com
This news is a press release provided by FUJIREBIO. Korea Newswire follows these editorial guidelines. FUJIREBIO News ReleasesSubscribeRSS 후지레비오, 연구 전용 완전 자동화 루미펄스® G GFAP 측정법 출시하며 신경 검사 포트폴리오 강화 H.U. 그룹 홀딩스(H.U. Group Holdings Inc.) 및 그룹이 모든 지분을 소유한 자회사 후지레비오(Fujirebio)는 오늘 완전 자동화, 임의 접근 루미펄스® G(LUMIPULSE® G) 면역측정 시스템에 루미펄스 G GFAP(Lumipulse G GFAP) 측정법을 이용할 수 있게 됐다고 발표했다. 이 연구 전용(RUO, Research Use Only) ... 7월 28일 10:50 Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative dis... 3월 13일 11:40 ... More  More News Health Biotechnology Pharmaceutical R&D Overseas FUJIREBIO All News Releases 